Article
Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Molecular cancer therapeutics - 2 Apr 2024
Ogimoto Tatsuya, Ozasa Hiroaki, Tsuji Takahiro, Funazo Tomoko, Yamazoe Masatoshi, Hashimoto Kentaro, Yoshida Hiroshi, Hosoya Kazutaka, Ajimizu Hitomi, Nomizo Takashi, Yoshida Hironori, Hamaji Masatsugu, Menju Toshi, Yoshizawa Akihiko, Date Hiroshi, Hirai Toyohiro
Abstract excerpt
EGFR-tyrosine kinase inhibitors (TKI) are the first-line therapies for EGFR mutation-positive lung cancer. EGFR-TKIs have favorable therapeutic effects. However, a large proportion of patients with EGFR mutation-positive lung cancer subsequently relapse. Some cancer cells survive the initial treatment with EGFR-TKIs, and this initial survival may be associated with subsequent recurrence. Therefore, we aimed to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.